Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2010-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00660803
- Locations
- 🇧🇷
Research Site, Sao Paulo, SP, Brazil
Second Line Breast Cancer Trial
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 588
- Registration Number
- NCT00635713
Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 116
- Registration Number
- NCT00629616
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷Hopital Dupuytren, Limoges Cedex, France
🇫🇷Centre Eugene Marquis, Rennes, France
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 26
- Registration Number
- NCT00617188
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Efficacy and Safety of 500mg of Fulvestrant
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00585507
- Locations
- 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Mara Chambers
- Target Recruit Count
- 33
- Registration Number
- NCT00570921
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
- Conditions
- Interventions
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 27
- Registration Number
- NCT00570258
- Locations
- 🇺🇸
Hackensack University, Hackensack, New Jersey, United States
🇺🇸St. Luke's Cancer Institute, Kansas City, Missouri, United States
🇺🇸NEA Clinic, Jonesboro, Arkansas, United States
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 380
- Registration Number
- NCT00545077
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇩🇪Klinikum Bayreuth, Bayreuth, Germany
🇩🇪Universitätsklinikum Charité, Berlin, Germany
Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 870
- Registration Number
- NCT00543127
- Locations
- 🇪🇸
Hospital de Sagunto, Sagunto, Valencia, Spain
🇪🇸Hospital Lluís Alcanyis, Xátiva, Valencia, Spain
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00534417
- Locations
- 🇺🇸
Augusta Oncology Associates, Augusta, Georgia, United States
🇺🇸Medical & Surgical Specialists, Galesburg, Illinois, United States
🇺🇸Oncology Specialists, Park Ridge, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.